Selected Publications

Braybroke, J. P., Propper, D. J., O'Byrne, K. J., Koukourakis, M. I., Patterson, A. V., Houlbrook, S., Love, S. D., Varcoe, S., Taylor, M., Ganesan, T. S., Talbot, D. C., and Harris, A. L. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha. Br J Cancer. 2000; 83: 219-224

Dunbar, P. R., Smith, C. L., Chao, D., Salio, M., Shepherd, D., Mirza, F., Lipp, M.,Lanzavecchia, A., Sallusto, F., Evans, A., Russell-Jones, R., Harris, A. L., and Cerundolo, V. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol. 2000; 165: 6644-6652.

Propper, D. J., Levitt, N. C., O'Byrne, K., Braybrooke, J. P., Talbot, D. C., Ganesan, T. S., Thompson, C. H., Rajagopalan, B., Littlewood, T. J., Dixon, R. M., and Harris, A. L. Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer. Br J Cancer 2000; 82: 1776-1782.

Harris, A. L., Reusch, P., Barleon, B., Hang, C., Dobbs, N., and Marme, D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res, 2000; 7: 1992-1997.

Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P.,Caponigro, F., Graf, P., Dutreix, C., Blackie, R., Kaye, S. B., Ganesan, T. S., Talbot, D. C., Harris, A. L., and Twelves, C. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol, 2001; 19: 1485-1492.